Latest Breaking News On - Investor relations corporate communications - Page 6 : comparemela.com

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Iovance-amtagvi
Jen-saunders
Sara-pellegrino
Exchange-commission
Iovance-biotherapeutics-inc
Drug-administration
Nasdaq
Investor-relations-corporate-communications
European-medicines-agency
Nasdaq-listing-rule
First-vesting-date
Private-securities-litigation-reform-act

Iovance Biotherapeutics Reports Inducement Grants under

Iovance Biotherapeutics Reports Inducement Grants under
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

Iovance-amtagvi
Jen-saunders
Sara-pellegrino
Investor-relations-corporate-communications
European-medicines-agency
Iovance-biotherapeutics-inc
Drug-administration
Exchange-commission
Nasdaq
Nasdaq-listing-rule
First-vesting-date
Private-securities-litigation-reform-act

Zealand Pharma Announces Financial Results for the First Quarter of 2024

Company announcement - No. 26 / 2024 Zealand Pharma Announces Financial Results for the First Quarter of 2024 Strong performance in the first quarter of 2024 paving the way for important data.

Denmark
United-states
Ukraine
Copenhagen
Køavn
Milan
Lombardia
Italy
Henriette-wennicke
Adam-steensberg
Zealand-pharma
David-kendall

Strong organic growth in core markets underscores resilience of Dermapharm Holding SE's corporate strategy

EQS-News: Dermapharm Holding SE / Key word: Quarterly / Interim Statement/Quarter Results Strong organic growth in core markets underscores resilience of Dermapharm Holding SE s.

Spain
Germany
United-states
Brehna
Sachsen-anhalt
Munich
Bayern
France
Friedrichsdorf
Mecklenburg-vorpommern
Spanish
Pharm-gmb

MS Pharma becomes Partner for the Commercialization of FYB203, Formycon's Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region

MS Pharma becomes Partner for the Commercialization of FYB203, Formycon's Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Canada
Japan
Jordan
Saudi-arabia
Switzerland
Munich
Bayern
Germany
Frankfurt
Brandenburg
Amman
O11